2021-2022

JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY KAKINADA
Result of II B.Pharmacy I semester (PCI) Supplementary Examinations July 2022
College name: VIJAYA INSTITUTE OF PHARMACEUICAL SCIENCES FOR WOMEN 7N

Htno	Subcode	Subname	Grade	Credits
187N1R0037	BP301T	PHARMACEUTICAL ORGANIC CHEMISTRY II	F	0
187N1R0037	BP304T	PHARMACEUTICAL ENGINEERING	F	0
197N1R0037	BP302T	PHYSICAL PHARMACEUTICS I	F	o
		PHARMACEUTICAL ORGANIC CHEMISTRY II	F	0
197N1R0010	BP301T	PHARMACEUTICAL ORGANIC CHEMISTRY II	F	0
197N1R0011	BP301T	PHARMACEUTICAL ORGANIC CHEMISTRY II	AB	0
197N1R0014	BP301T	PHARMACEUTICAL ORGANIC CHEMISTRY II	F	0
197N1R0025	BP301T	PHARMACEUTICAL ORGANIC CHEMISTRY II	F	0
197N1R0038	BP301T	PHYSICAL PHARMACEUTICS I	F	0
197N1R0038	BP302T	PHARMACEUTICAL ORGANIC CHEMISTRY II	F	0
197N1R0042	BP301T	PHARMACEUTICAL ENGINEERING	AB	0
19 7N1 R0042	BP304T	PHARMACEUTICAL ENGINEERING PHARMACEUTICAL ORGANIC CHEMISTRY II	AB	0
197N1R0043	BP301T	PHARMACEUTICAL ORGANIC CHEMISTRY II	F	0
197N1R0051	BP301T	PHARMACEUTICAL ORGANIC CHEMISTRY II	F	0
197N1R0056	BP301T	PHARMACEUTICAL ORGANIC CHEMISTRY II	F	0
19 7N1 R0059	BP301T	PHARMACEUTICAL ORGANIC CHEMISTRY II	F	0
197N1R0075	BP301T	PHARMACEUTICAL ORGANIC CHEMISTRY II	F	0
197N1R0079	BP301T	PHARMACEUTICAL ORGANIC CHEMISTRY II	F	0
197N1R0085	BP301T	PHARMACEUTICAL ORGANIC CHEMISTRY II	F	0
207N1R0028	BP302T	PHYSICAL PHARMACEUTICS I	D	4
207N1R0028	BP303T	PHARMACEUTICAL MICROBIOLOGY	0	2
207N1R0039	BP305P	PHARMACEUTICAL ORGANIC CHEMISTRY II LAB	0	2
207N1R0039	BP306P	PHYSICAL PHARMACEUTICS I LAB	A	2
207N1R0039	BP307P	PHARMACEUTICAL MICROBIOLOGY LAB	В	2
207N1R0039	BP308P	PHARMACEUTICAL ENGINEERING LAB	F	0
207N1R0073	BP303T	PHARMACEUTICAL MICROBIOLOGY	1,	1

^{**}Note:1)[Last Date to apply for Recounting/Revaluation/Challenge Revaluation is : 08-10-2022]

- ** Note:**
- * -1 in the filed of externals indicates student is absent for the respective subject.
- * -2 in the filed of externals indicates student result Withheld for the respective subject.
- * -3 in the filed of externals indicates student involved in Malpractice for the respective subject.

Controller of Examinations

Poglat a lelle

VIJAYA INSTITUTE PHARMACEUTICAL SCIENCES FOR WOMEN ENIKEPADU, VIJAYAWADA - 521 108



JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY KAKINADA

Result of IV B.Pharmacy I Semester (PCI) Adv.Supplementary Examinations May 2022
College name: VIJAYA INSTITUTE OF PHARMACEUICAL SCIENCES FOR WOMEN:7N

Н	tno	Subcode	Subname	Grade	Credits	
1	77N1R0054	BP701T	INSTRUMENTAL METHODS OF ANALYSIS - THEOR	D	4] -
1	77N1R0054	BP703T	PHARMACY PRACTICE - THEORY	F	0	
17	77N1R0054	BP704T	NOVEL DRUG DELIVERY SYSTEM - THEORY	F	0	1
17	77N1R0056	BP701T	INSTRUMENTAL METHODS OF ANALYSIS - THEOR	D	4	
17	77N1R0058	BP701T	INSTRUMENTAL METHODS OF ANALYSIS - THEOR	D	4	
17	77N1R0069	BP702T	INDUSTRIAL PHARMACYII - THEORY	F	0	
17	77N1R0069	BP703T	PHARMACY PRACTICE - THEORY	F	0	
17	77N1R0081	BP703T	PHARMACY PRACTICE - THEORY	C	4	
17	77N1R0083	BP701T	INSTRUMENTAL METHODS OF ANALYSIS - THEOR	D	4	1
17	77N1R0091	BP701T	INSTRUMENTAL METHODS OF ANALYSIS - THEOR	AB	0	
17	77N1R0091	BP703T	PHARMACY PRACTICE - THEORY	AB	0	
18	7N1R0007	BP704T	NOVEL DRUG DELIVERY SYSTEM - THEORY	F	0	
10000	37N1R0013	BP703T	PHARMACY PRACTICE - THEORY	D	4	
Name of Street	37N1R0016	BP703T	PHARMACY PRACTICE - THEORY	D	4	D.
900	37N1R0020	BP703T	PHARMACY PRACTICE - THEORY	D	4	,
	37N1R0022	BP701T	INSTRUMENTAL METHODS OF ANALYSIS - THEOR	D	4	
	37N1R0022	BP702T	INDUSTRIAL PHARMACYII - THEORY	F	0	
1	37N1R0022	BP703T	PHARMACY PRACTICE - THEORY	District Control of		
1	37N1R0022	BP704T	A STATE OF THE STA	F	0	
1000	37N1R0022	programme and the	NOVEL DRUG DELIVERY SYSTEM - THEORY	F	0	
St. Allert		BP703T	PHARMACY PRACTICE - THEORY	F	0	
Title 1	37N1R0024	BP701T	INSTRUMENTAL METHODS OF ANALYSIS - THEOR	D	4	
100	37N1R0024	BP702T	INDUSTRIAL PHARMACYII - THEORY	D	4	
100	37N1R0024	BP703T	PHARMACY PRACTICE - THEORY	F	0	
-	37N1R0037	BP701T	INSTRUMENTAL METHODS OF ANALYSIS - THEOR	D	4	
13000	37N1R0037	BP703T	PHARMACY PRACTICE - THEORY	D	4	-
18	37N1R0037	BP704T	NOVEL DRUG DELIVERY SYSTEM - THEORY	F	0	
200	37N1R0047	BP701T	INSTRUMENTAL METHODS OF ANALYSIS - THEOR	D	4	
18	37N1R0047	BP704T	NOVEL DRUG DELIVERY SYSTEM - THEORY	F	0	
18	37N1R0049	BP703T	PHARMACY PRACTICE - THEORY	D	4	(3)
18	37N1R0049	BP704T	NOVEL DRUG DELIVERY SYSTEM - THEORY	D	4	7
18	37N1R0050	BP703T	PHARMACY PRACTICE - THEORY	D	4	
18	7N1R0050	BP704T	NOVEL DRUG'DELIVERY SYSTEM - THEORY	D	4	
18	7N1R0056	BP703T	PHARMACY PRACTICE - THEORY	D	4	P
18	7N1R0056	BP704T	NOVEL DRUG DELIVERY SYSTEM - THEORY	D	4	A
18	7N1R0061	BP703T	PHARMACY PRACTICE - THEORY	C	4	
	7N1R0063	BP703T	PHARMACY PRACTICE - THEORY	F	0	
-	7N1R0063	BP704T	NOVEL DRUG DELIVERY SYSTEM - THEORY	F	0	
1	7N1R0067	BP701T	INSTRUMENTAL METHODS OF ANALYSIS - THEOR			
10000	7N1R0067	BP703T	PHARMACY PRACTICE - THEORY	CM	4	To
F 50000	7N1R0068	BP7031	THE RESERVE OF THE PROPERTY OF	D		
1000	CONTRACTOR OF STREET	BP703T	PHARMACY PRACTICE - THEORY	DPR	ACIPAL	
	TN1R0071	per with which the real ways to	PHARMACY PRACTICE - THEORY VIJA	PA IN	STIT	UTE (
		BP703T	PHARMACY PRACTICE - THEORY PHARMA	OEUTICA	9CIENCE	FOR WO
	7V1R0085	BP701T	INSTRUMENTAL METHODS OF ANALYSIS - THEORE	province of the later.	HAYAWA!	PA-521 1
11 200	PN1F6085	BP703T	PHARMACY PRACTICE - THEORY	D	4	
[18	7N176066	BP703T	PHARMACY PRACTICE - THEORY	D	4	A

**Note:1)[Last Date to apply for Recounting/Revaluation/Challenge Revaluation is : 15-07-2022]

- ** Note:**
- * -1 in the filed of externals indicates student is absent for the respective subject.
- * -2 in the filed of externals indicates student result Withheld for the respective subject.
- * -3 in the filed of externals indicates student involved in Malpractice for the respective subject.

Date:07.07.2022

Controller of Examinations

lighet a help

VIJAYA INSTITUTE OF
PHARMACEUTICAL SCIENCES FOR WOMEN
ENIKEPADU. VIJAYAWADA-521 108.



AWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY KAKINADA
Result of III B, Pharmacy II SEMESTER (PCI) EXAMINATIONS, FEB.-2022
College name: VIJAYA INSTITUTE OF PHARMACEUICAL SCIENCES FOR WOMEN:7N

Htno	Subcode	Subname	Grade	Credits
177N1R0069	BP601T	MEDICINAL CHEMISTRY III - THEORY	AB	0
177N1R0069	BP604T	BIOPHARMACEUTICS AND PHARMACOKINETICS	AB	0
177N1R0069	BP606T	QUALITY ASSURANCE -THEORY	AB	0
177N1R0076	BP606T	QUALITY ASSURANCE -THEORY	D	4
187N1R0003	BP601T	MEDICINAL CHEMISTRY III - THEORY	F	0
187N1R0003	BP606T	QUALITY ASSURANCE -THEORY	D	4
187N1R0007	BP601T	MEDICINAL CHEMISTRY III - THEORY	F	0
187N1R0011	BP601T	MEDICINAL CHEMISTRY III - THEORY	D	4
187N1R0013	BP601T	MEDICINAL CHEMISTRY III - THEORY	F	0
187N1R0016	BP601T	MEDICINAL CHEMISTRY III - THEORY	F	0
187N1R0016	BP607P	MEDICINAL CHEMISTRY III - PRACTICAL	A	2
187N1R0016	BP608P	PHARMACOLOGY III - PRACTICAL	A	2
187N1R0022	BP601T	MEDICINAL CHEMISTRY III - THEORY	F	0
187N1R0022	BP604T	BIOPHARMACEUTICS AND PHARMACOKINETICS	F	0
187N1R0022	BP606T	QUALITY ASSURANCE -THEORY	F	A-T-HELYTESSYR
187N1R0023	BP601T	MEDICINAL CHEMISTRY III - THEORY	F	0
187N1R0023	BP604T	BIOPHARMACEUTICS AND PHARMACOKINETICS	F	0
187N1R0029	BP606T	QUALITY ASSURANCE -THEORY	CONTRACTOR OF THE PARTY OF	0
187N1R0033	BP606T	QUALITY ASSURANCE -THEORY	C	4
187N1R0035	-	QUALITY ASSURANCE -THEORY	С	4
187N1R0036	BP604T	BIOPHARMACEUTICS AND PHARMACOKINETICS	D	4
probability and the same	BP605T		F	0
187N1R0036	The same of the sa	PHARMACEUTICAL BIOTECHNOLOGY - THEORY	D	4
187N1R0037	BP604T	QUALITY ASSURANCE -THEORY	С	4
187N1R0037	BP605T	BIOPHARMACEUTICS AND PHARMACOKINETICS	F	0
187N1R0037	THE ROOM OF SHARE SHAPE	PHARMACEUTICAL BIOTECHNOLOGY - THEORY	D	4
	BP606T	QUALITY ASSURANCE -THEORY	D	4
the Control of the Co	BP606T	QUALITY ASSURANCE -THEORY	C	4
187N1R0043	Street Street, Square,	QUALITY ASSURANCE -THEORY	C	4
187N1R0044	BP606T	QUALITY ASSURANCE -THEORY	D	4
187N1R0045	BP607P	MEDICINAL CHEMISTRY III - PRACTICAL	C	2
187N1R0045	BP608P	PHARMACOLOGY III - PRACTICAL	C	2
THE RESERVE OF THE PARTY OF THE	BP609P	HERBAL DRUG TECHNOLOGY - PRACTICAL	C	2
g.f. septiment makes provinced	BP606T	QUALITY ASSURANCE -THEORY	В	4
	BP601T	MEDICINAL CHEMISTRY III - THEORY	F	0
purchase street representative despisations.	BP602T	PHARMACOLOGY III - THEORY	F	0
1 profit time, supply 1 / Artist Sept. (1)	BP604T	BIOPHARMACEUTICS AND PHARMACOKINETICS	AB	0
STATE OF THE PARTY	BP605T	PHARMACEUTICAL BIOTECHNOLOGY - THEORY	AB	0
	BP606T	QUALITY ASSURANCE -THEORY	D	4
187N1R0048	BP606T	QUALITY ASSURANCE -THEORY	Section of the last	4
187N1R0049	BP601T	MEDICINAL CHEMISTRY III - THEORY	- 10	0
187N1R0049	BP605T	PHARMACEUTICAL BIOTECHNOLOGY - THEORY	c	4_01
187N1R0049	PAYTHER CONTRACTOR AND INC.	Chippophia (grantes) Albania (grantes) and comment and control of the control of	ABRIN	OIPAL
A COTAMA POLICION			AINS	TUTIT
YAWADA OF	BP605T	PHARMACEUTICAL BIOTECHNOLOGY - THEORY C	LTICAL S	JENCES O
187N1R0050		QUALITY ASSURANCE -THEORY ENIKEPA	DU. VIJA	YAWADA-

Htno	Subcode	Subname	Grade	Credits
187N1R0051	BP601T	MEDICINAL CHEMISTRY III - THEORY	F	0
187N1R0051	BP606T	QUALITY ASSURANCE -THEORY	D	4
187N1R0054	BP601T	MEDICINAL CHEMISTRY III - THEORY	F	0
187N1R0056	BP601T	MEDICINAL CHEMISTRY III - THEORY	F	0
187N1R0056	BP602T	PHARMACOLOGY III - THEORY	F	0
187N1R0057	BP601T	MEDICINAL CHEMISTRY III - THEORY	F	0
187N1R0057	BP606T	QUALITY ASSURANCE -THEORY	F	0
187N1R0058	BP606T	QUALITY ASSURANCE -THEORY	D	4
187N1R0059	BP606T	QUALITY ASSURANCE -THEORY	D	4
187N1R0060	BP601T	MEDICINAL CHEMISTRY III - THEORY	С	4
187N1R0060	BP606T	QUALITY ASSURANCE - THEORY	C	4
187N1R0061	BP601T	MEDICINAL CHEMISTRY III - THEORY	D	4
187N1R0063	BP601T	MEDICINAL CHEMISTRY III - THEORY	F	0
187N1R0063	BP606T	QUALITY ASSURANCE -THEORY	D	4
187N1R0067	BP601T	MEDICINAL CHEMISTRY III - THEORY	F	0
187N1R0067	BP604T	BIOPHARMACEUTICS AND PHARMACOKINETICS	F	0
187N1R0068	BP601T	MEDICINAL CHEMISTRY III - THEORY	F	0
187N1R0068	BP604T	BIOPHARMACEUTICS AND PHARMACOKINETICS	F	0
187N1R0068	BP605T	PHARMACEUTICAL BIOTECHNOLOGY - THEORY	D	4
187N1R0068	BP606T	QUALITY ASSURANCE -THEORY	С	4
187N1R0071	BP601T	MEDICINAL CHEMISTRY III - THEORY	D	4
187N1R0071	BP607P	MEDICINAL CHEMISTRY III - PRACTICAL	С	2
187N1R0071	BP608P	PHARMACOLOGY III - PRACTICAL	В	2
187N1R0073	BP601T	MEDICINAL CHEMISTRY III - THEORY	D	4
187N1R0073	BP604T	BIOPHARMACEUTICS AND PHARMACOKINETICS	F	0
187N1R0076	BP601T	MEDICINAL CHEMISTRY III - THEORY	D	4
187N1R0077	BP605T	PHARMACEUTICAL BIOTECHNOLOGY - THEORY	С	4
187N1R0079	BP606T	QUALITY ASSURANCE -THEORY	С	4
187N1R0080	BP606T	QUALITY ASSURANCE -THEORY	С	4
187N1R0081	BP606T	QUALITY ASSURANCE -THEORY	С	4
187N1R0081	BP607P	MEDICINAL CHEMISTRY III - PRACTICAL	С	2
187N1R0081	BP608P	PHARMACOLOGY III - PRACTICAL	В	2
187N1R0082	BP606T	QUALITY ASSURANCE -THEORY	C	4
187N1R0083	BP606T	QUALITY ASSURANCE -THEORY	С	4
187N1R0085	BP601T	MEDICINAL CHEMISTRY III - THEORY	D	4
187N1R0085	BP604T	BIOPHARMACEUTICS AND PHARMACOKINETICS	F	0
187N1R0085	BP606T	QUALITY ASSURANCE -THEORY	C	4
187N1R0086	BP601T	MEDICINAL CHEMISTRY III - THEORY	F	0
187N1R0086	BP606T	QUALITY ASSURANCE -THEORY	C	4

^{**}Note:1)[Last Date to apply for Recounting/Revaluation/Challenge Revaluation is : 02-05-2022]

* -2 in the filed of externals indicates student result Withheld for the respective subject.

* -3 in the filed of external indicates student involved in Malpractice for the respective subject.

VIJAYA INSTITUTE OF
PHARIJACEUTICAL SCIENCES FOR WOLLEN
ENIMEPROU VUAYAWADA-521 10%

^{**} Note:**

^{* -1} in the filed of externals indicates student is absent for the respective subject.



JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY KAKINADA
RESULTS OF PharmD I Year Examinations April-2022
College name: VIJAYA INSTITUTE OF PHARMACEUICAL SCIENCES FOR WOMEN:7N

	Htno	Subcode	Subname	Internal	External	CREDITS
	187N1T0010			15	30	0
		T1104	PHARMACEUTICAL ORGANIC CHEMISTRY	26	57	0
	187N1T0010	T110B	PHARMACEUTICAL ORGANIC CHEMISTRY LAB	15	9	0
	187N1T0013	T1104	PHARMACEUTICAL ORGANIC CHEMISTRY	25	54	0
	187N1T0013	T110B	PHARMACEUTICAL ORGANIC CHEMISTRY LAB	17	13	0
	187N1T0014	T1104	PHARMACEUTICAL ORGANIC CHEMISTRY	20	57	0
	187N1T0014	T110B	PHARMACEUTICAL ORGANIC CHEMISTRY LAB	15	-1	0
	187N1T0024	T1104	PHARMACEUTICAL ORGANIC CHEMISTRY	24	-1	0
-	187N1T0024	T110B	PHARMACEUTICAL ORGANIC CHEMISTRY LAB	22	9	0
	197N1T0016	T1104	PHARMACEUTICAL ORGANIC CHEMISTRY	26	54	0
	197N1T0016	T110B	PHARMACEUTICAL ORGANIC CHEMISTRY LAB		44	
	197N1T0024	T1101	HUMAN ANATOMY AND PHYSIOLOGY	10	22	0
	197N1T0024	T1104	PHARMACEUTICAL ORGANIC CHEMISTRY	20	177	1
	197N1T0024	T1108	HUMAN ANATOMY AND PHYSIOLOGY LAB	29	55 55	0
	197N1T0024	T110B	PHARMACEUTICAL ORGANIC CHEMISTRY LAB	27	55	1
	207N1T0001	T1101	HUMAN ANATOMY AND PHYSIOLOGY	16	46	0
	207N1T0001	T1102	PHARMACEUTICS	22	25	0
	207N1T0001	T1103	MEDICINAL BIOCHEMISTRY	19	26	
	207N1T0001	T1104	PHARMACEUTICAL ORGANIC CHEMISTRY	23	30	1
	207N1T0001	T1106	REMEDIAL MATHEMATICS	24	17	0
	207N1T0001	T1108	HUMAN ANATOMY AND PHYSIOLOGY LAB	22	50	1
	207N1T0001	T1109	PHARMACEUTICS LAB	29	60	0
	207N1T0001	T110A	MEDICINAL BIOCHEMISTRY LAB	26	57	0
	207N1T0001	T110B	PHARMACEUTICAL ORGANIC CHEMISTRY LAB	27	55	1
á	207N1T0002	T1104	PHARMACEUTICAL ORGANIC CHEMISTRY	22	30	1
180	207N1T0002	T110B	PHARMACEUTICAL ORGANIC CHEMISTRY LAB	28	59	1
d	207N1T0003	T1102	PHARMACEUTICS	24	36	1
d	207N1T0003	T1104	PHARMACEUTICAL ORGANIC CHEMISTRY	26	37	1
	207N1T0003	T1109	PHARMACEUTICS LAB	29	61	1
	207N1T0003	T110B	PHARMACEUTICAL ORGANIC CHEMISTRY LAB	27	56	1
	207N1T0003	T1104	PHARMACEUTICAL ORGANIC CHEMISTRY	25	31	1
	207N1T0004	T110B	PHARMACEUTICAL ORGANIC CHEMISTRY LAB	26	57	1
	207N1T0004	T1104	PHARMACEUTICAL ORGANIC CHEMISTRY	27	44	1
	207N1T0005	T110B	PHARMACEUTICAL ORGANIC CHEMISTRY LAB	27	57	1
		T1101	HUMAN ANATOMY AND PHYSIOLOGY	14	44	1
á	207N1T0006	T1102	PHARMACEUTICS	19	19	0
	207N1T0006	T1102	MEDICINAL BIOCHEMISTRY	13	13	0
	207N1T0006		PHARMACEUTICAL ORGANIC CHEMISTRY	24	18	0
	207N1T0006	T1104	BHARMACEUTICAL INORGANIC CHEMISTRY	11	30	0
	207N1T0006	1/2/11/2	A A THE MATICE	25/1	17	0
	207N1T0006	T1106	HI MANIANATOMY AND PHYSIOLOGY LAB	25	54 all	31
	207N1T0006	时108 里 ENIK	HUMAN AMATOMY AND PHYSIOLOGY LAB	28 ATA		0
	207N1T0006	[型[V]JAY		As IN	FITU	
	207N1T0006	T3.10A	PHARMACEUTICAL ORGANIC CHEMISTRYPHARMAC			
	207N1T0006	TY 10B	PHARMACEUTICAL INORGANIC CHEMISTENIKATO	PSO VIEW	VIENUES F	OR WOMEN
	207N1T0006		PHARMACEUTICAL ORGANIC CHEMISTRY	28	44	1
	207N1T0007	T1104	PHARMACEUTICAL ORGANIO OFFEMIOTICE	20		

Htno	Subcode	Subname			
207N1T0007	T110B		Internal	External	CREDITS
207N1T0008	T1102	PHARMACEUTICAL ORGANIC CHEMISTRY LAB	27 .	58	1
207N1T0008	T1103	PHARMACEUTICS	15	17	0
		MEDICINAL BIOCHEMISTRY	17	18	0
207N1T0008	T1104	PHARMACEUTICAL ORGANIC CHEMISTRY	23	16	0
207N1T0008	T1105	PHARMACEUTICAL INORGANIC CHEMISTRY	22	30	1
207N1T0008	T1106	REMEDIAL MATHEMATICS	23	19	0
207N1T0008	T1109	PHARMACEUTICS LAB	29	61	0
207N1T0008	T110A	MEDICINAL BIOCHEMISTRY LAB	25	62	0
207N1T0008	T110B	PHARMACEUTICAL ORGANIC CHEMISTRY LAB	26	57	0
207N1T0008		PHARMACEUTICAL INORGANIC CHEMISTRY LAB	24	57	1
207N1T0010		PHARMACEUTICAL ORGANIC CHEMISTRY	26	35	1
207N1T0010	and the state of t	PHARMACEUTICAL ORGANIC CHEMISTRY LAB	28	57	1
		HUMAN ANATOMY AND PHYSIOLOGY	11	36	0
207N1T001		•	13	19	0
207N1T001	1	PHARMACEUTICS	16	18	0
207N1T001	1	MEDICINAL BIOCHEMISTRY	13	30	0
207N1T001		PHARMACEUTICAL ORGANIC CHEMISTRY	11	31	0
207N1T001	1	PHARMACEUTICAL INORGANIC CHEMISTRY	14	30	0
207N1T001		REMEDIAL MATHEMATICS	27	56	0
207N1T001	1	HUMAN ANATOMY AND PHYSIOLOGY LAB	23	58	0
207N1T001	1	PHARMACEUTICS LAB	24	59	0
207N1T001	11 T110A	MEDICINAL BIOCHEMISTRY LAB	27	53	0
207N1T00	11 T110B	PHARMACEUTICAL ORGANIC CHEMISTRY LAB	24	59	0
207N1T00	11 T110C	PHARMACEUTICAL INORGANIC CHEMISTRY LAB	17	34	1
207N1T00	12 T1102	PHARMACEUTICS PHARMACEUTICS PHARMACEUTICS PHARMACEUTICS	25	26	1
207N1T00	12 T1104	PHARMACEUTICAL ORGANIC CHEMISTRY	23	26	0
207N1T00	12 T1106	REMEDIAL MATHEMATICS	30	57	1
207N1T00	1	PHARMACEUTICS LAB PHARMACEUTICAL ORGANIC CHEMISTRY LAB	28	56	1
207N1T00	1		28	34	1
The state of the s	14 T1106	REMEDIAL MATHEMATICS HUMAN ANATOMY AND PHYSIOLOGY	13	35	0
207N1T00	į.		19	21	0
207N1T00	1	- LOCALITA MOTENY	20	21	0
207N1T00		OPENIC CHEMISTRY	27	26	1
207N1T00		INOPGANIC CHEMISTRY	22	30	1
207N1T00		AND DUVEIOLOGY LAB	24	52	0
207N1T00	ł		30	57	0
207N1T00	4	PLOCHEMISTRY AR	25	57	0
207N1T00	§ .	CHEMISTRY LAB	26	55	1
207N1T00		THE ALL INCREANCE CHEMISTRY LAF	26	61	1
207N1T00	(THE THEORY OF LITICS	19	28	0
207N1T0		INCREASING CHEMISTRY	24	40	1
1	019 T1105		26	35	1
207N1T0	1		30	61	0
207N1T0	1	PALA OF UTICAL INOPGANIC CHEMISTRY LAI	3 30	63	1
207N1T0	1	THE PARACEUTICS	16	23	0
207N1T0		NO CHENICIPY	17	28	0
	021 T110	A DOLLAR ON THE PROPERTY	24	30	1
20/N110	TARO TARO	THE MATICE	220	30	1
20/N110	THAN THAN	NAME BHARMACEUTICS LAB VIJAYA	RINC	PA 67	0
		SAVADAIA SI	INST	THAT	E (0
	027 7110	A CHEMIC CHEMICAGE	CAL SCIE	ICC SEC.	1
1 710 78 (4 T	021 1410	SK JOW PADU.	VIJAYAV	VADA - 52	14 400

Htno	Subcode	Subname	Into			
207N1T0022	T1101	HUMAN ANATOMY AND PHYSIOLOGY	Inter		ernal	CREDI
207N1T0022	T1103	MEDICINAL BIOCHEMISTRY	12	40		1
207N1T0022	T1104	PHARMACEUTICAL ORGANIC CHEMISTRY	19	25		0
207N1T0022			20	31	-	1
A PART CARE OF		HUMAN ANATOMY AND PHYSIOLOGY LAB	23	52	1	
207N1T0022	1	MEDICINAL BIOCHEMISTRY LAB	25	56	0	
207N1T0022	T110B	PHARMACEUTICAL ORGANIC CHEMISTRY LAB	28	56	1	
207N1T0023	T1104	PHARMACEUTICAL ORGANIC CHEMISTRY	26	31	11	
207N1T0023	1	PHARMACEUTICAL ORGANIC CHEMISTRY LAB	26	56	1	
207N1T0024		PHARMACEUTICS	20	18	0	
207N1T002	1	MEDICINAL BIOCHEMISTRY	16	15	0	
207N1T0024	1	PHARMACEUTICAL ORGANIC CHEMISTRY	20	14	0	
207N1T0024	1	PHARMACEUTICAL INORGANIC CHEMISTRY	25	32	1	
207N1T002		REMEDIAL MATHEMATICS	25	30	1	
207N1T002	4 T1109	PHARMACEUTICS LAB	29	56	0	- 11 11 11 11
207N1T002	4 T110A	MEDICINAL BIOCHEMISTRY LAB	25	54	0	
207N1T002	4 T110B	PHARMACEUTICAL ORGANIC CHEMISTRY LAB	27	51	0	
207N1T002	4 T110C	PHARMACEUTICAL INORGANIC CHEMISTRY LAB	26	61	1	
207N1T002	5 T1102	PHARMACEUTICS	12	31	0	
207N1T002	5 T1103	MEDICINAL BIOCHEMISTRY	9	20	0	
207N1T002	5 T1104	PHARMACEUTICAL ORGANIC CHEMISTRY	20	12	0	
207N1T002	5 T1106	REMEDIAL MATHEMATICS	17	14	0	
207N1T002	5 T1109	PHARMACEUTICS LAB	30	62	0	
207N1T002	5 T110A	MEDICINAL BIOCHEMISTRY LAB	25	58	0	
207N1T002		PHARMACEUTICAL ORGANIC CHEMISTRY LAB	28	55	0	
207N1T002	1	PHARMACEUTICS	14	28	0	
207N1T002		MEDICINAL BIOCHEMISTRY	13	17	0	
207N1T002		PHARMACEUTICAL ORGANIC CHEMISTRY	11	21	0	
207N1T002		REMEDIAL MATHEMATICS	16 29	13 59	0	
207N1T002		PHARMACEUTICS LAB	26	55	0	
207N1T002 207N1T002		MEDICINAL BIOCHEMISTRY LAB PHARMACEUTICAL ORGANIC CHEMISTRY LAB	28	56	0	
207N1T002	enable executive translation fil	PHARMACEUTICS PHARMACEUTICS	22	40	1	1950534
207N1T002		PHARMACEUTICAL ORGANIC CHEMISTRY	26	39	1	
207N1T002	- 100	PHARMACEUTICS LAB	29	61	1	
207N1T0028		PHARMACEUTICAL ORGANIC CHEMISTRY LAB	28	58	1	
207N1T0029	T1101	HUMAN ANATOMY AND PHYSIOLOGY	10	43	1	
207N1T0029	71102	PHARMACEUTICS	18	10	0	
207N1T0029	T1103	MEDICINAL BIOCHEMISTRY	15	18	0	
207N1T0029	T1104	PHARMACEUTICAL ORGANIC CHEMISTRY	18	16	0	
207N1T0029	T1105	PHARMACEUTICAL INORGANIC CHEMISTRY	20	22	0	
207N1T0029	T1106	REMEDIAL MATHEMATICS	20	2	0	
207N1T0029	T1108	HUMAN ANATOMY AND PHYSIOLOGY LAB	23	58	1	
207N1T0029		PHARMACEUTICS LAB	29	58 57	0	
207N1T0029	T110A	MEDICINAL BIOCHEMISTRY LAB	25 24	54	0	
207N1T0029		PHARMACEUTICAL ORGANIC CHEMISTRY LAB	26	62	0	
207N1T0029	T110C	PHARMACEUTICAL INORGANIC CHEMISTRY LAB	20	\ \		

**Note:1)[Last Date to apply for Recounting/Revaluation/Challenge Revaluation is : 24-05-2022]

** Note:**

ENIKEPADU

PRINCIPAL
VIJAYA INSTITUTE OF
PHARMACEUTICAL SCIENCES FOR WOMEN
ENIKEPADU, VIJAYAWADA - 521 10



JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY KAKINADA RESULTS OF Pharmd III Year (R10) Examinations March-2022 College name: VIJAYA INSTITUTE OF PHARMACEUICAL SCIENCES FOR WOMEN:7N

Htno	Subcode	Subname	Internal	External	CREDITS
187N1T0007	T3103	PHARMACOTHERAPEUTICS-II	24	27	1
187N1T0007	T3105	MEDICAL CHEMISTRY	20	10	0
187N1T0007	T3109	PHARMACOTHERAPEUTICS-II LAB	27	60	1
187N1T0007	T3110	MEDICAL CHEMISTRY LAB	27	52	0
187N1T0013	T3103	PHARMACOTHERAPEUTICS-II	23	21	0
187N1T0013	T3109	PHARMACOTHERAPEUTICS-II LAB	26	59	0

^{**}Note:1)[Last Date to apply for Recounting/Revaluation/Challenge Revaluation is : 11-05-2022]

- * -1 in the filed of externals indicates student is absent for the respective subject.
- * -2 in the filed of externals indicates student result Withheld for the respective subject.
- * -3 in the filed of externals indicates student involved in Malpractice for the respective subject.

Date:05.05.2022

Controller of Examinations

lighest a. helle

ENIKEPADU

VIJAYA INSTITUTE OF PHARMACEUTICAL SCIENCES FOR WOMEN ENIKEPADU, VIJAYAWADA - 521 108

^{**} Note:**





K. Emilio

Registration No

6210055247

Candidate's Name:

KUNDETI SUSMITHA

Father's Name

KUNDETI RATNAM

Address

1/34/5,

V.R.S&Y.R.N COLLEGE, MAIN GATE

ENTRANCE,

CHIRALA,

BAPATLA.

ANDHRA PRADESH - 523157

Hall Ticket Number

Local Area

7190370347

AU

Category

SC

Gender

FEMALE

Date of Birth

01/02/2001

Subject Code	PY	Subject Name	PHARMACY	 	

Marks	35	Rank in Words Seven * Eight * Four	Rank in	784
Obtained			Figure	

PRINCIPAL VIJAYA INSTITUTE OF PHARMACEUTICAL SCIENCES FOR WO ENIKEPADU. VIJAYAWADA-521





AP PGECET - 2022 RANK CARD

(Conducted by Sri Venkateswara University, Tirupati)



Registration No

6210041097

Candidate's Name

KODIDATI SUSAN DEEPTHI

Father's Name

KODIDATI VENKATRATNAM

Address

20-306,

KANURU,

VIJAYAWADA,

KRISHNA,

ANDHRA PRADESH - 520007

Hall Ticket Number

7190370295

Local Area

AU

Category

SC


Gender

FEMALE

Date of Birth

09/09/1999





e	Cod	ect	bi	Su	
---	-----	-----	----	----	--

PY

Subject Name

PHARMACY

Marks Obtained 34

Rank in Words

Eight * Eight * Three

Rank in Figure

883



PRINCIPAL VIJAYA INSTITUTE OF

PHARMACEUTICAL SCIENCES FOR V. C

ENIKEPADU, VIJAYAWADA 5





Registration No

6210039520

Candidate's Name :

AVULA VARA LAKSHMI

Father's Name

AVULA LINGAJAH

Address

2-20.

NTR COLONY, AGRAHARAM VILLAGE,

JAGGAYYAPETA,

NTR.

ANDHRA PRADESH - 521175

Hall Ticket Number 7190370024

Local Area

AU

Category

BC_D

Gender

FEMALE

Date of Rirth

07/10/1999

Subject Code	PY	Subject Name PHARMACY		
Marks Obtained	34	Rank in Words Eight * Eight * Three	Rank in Figure	883

PRINCIPAL
VIJAYA INSTITUTE C
PHARMACEUTICAL SCIENCES FOR WO ENIKEPADU, VIJAYAWADA-521 1 **







Registration No

6210031107

Candidate's Name :

SHAIK RAZIVA BEGUM

Father's Name

SHAIK MASTHAN

Address

77-3-14

PIPULA ROAD.

AJITH SINGH NAGAR, VIJAYAWADA.

KRISHNA.

ANDHRA PRADESH - 520015

Hall Ticket Number 7190370598

Local Area

AU

Category

BC B

Gender

FEMALE

Date of Birth

12/03/2001



	Fra./	100	den	

Subject Code	PY	Subject Name	PHARMACY

Marks Obtained	33	Rank in Words	Nine * Seven * One	Rank in Figure 971	

PRINCIPAL

VIJAYA INSTITUTE OF

PHARMACEUTICAL SCIENCES FOR WON'EN ENIKEPADU. VIJAYAWADA-521 104

ENIKEPADU ENIKEP

(Ma





Registration No

6210035656

Candidate's Name:

RACHAMALLA SAI PRASANNA

Father's Name

RACHAMALLA VENKATA SIVA GOVINDA

Address

RAJULU

DOOR NO 8-4

MALLAVOLU VILLAGE,

GUDURU MANDALAM.

KRISHNA.

ANDHRA PRADESH - 521162

Hali Ticket Number 7190370541

Local Area

AU

Category

OC

Gender

FEMALE

Date of Birth

23/09/1999



R- Salprosanna

Subject Code	PY	Subject Name	PHARMACY		
Marks Obtained	32	Rank in Words	One * Zero * Six * Three	Rank in Figure	1063









Registration No

6210031947

Candidate's Name

MADUGULA KAVYA

Father's Name

: MADUGULA KRISHNA RAO

Address

: 44/14/59.

INDHERA PRIYADARSHI STREET.

GUNADHALA CENTER.

VIJAYAWADA URBAN

NTR.

ANDHRA PRADESH - 520004

Hall Ticket Number

7190370373

Local Area

AU

Category

SC

Gender

FEMALE

Date of Birth

25/04/2000

Subject Code	PY	Subject Name	РНАКМАСУ		
Marks Obtained	29	Rank in Words	One * Two * Four * Eight	Rank in Figure	1248

PRINCIPAL VIJAYA INSTITUTE C

PHARMACEUTICAL SCIENCES FOR WOLE

ENIKEPADU. VIJAYAWADA-521 1

CHEST !

ENIKEPADU CONTRACTOR OF THE PROPERTY OF THE PR

argu





Registration No

6210035688

Candidate's Name

NAMBURI KRISHNA VENI

Father's Name

NAMBURI SANGAMAIAH

Address

10-106,

KAPTHANUPALEM VILLAGE,

MOPIDEVI MANDAL,

KRISHNA,

ANDHRA PRADESH - 521125

Hall Ticket Number

7190370450

Local Area

AU

Category

ST

Gender

FEMALE

Date of Birth

15/08/2001



N. Krishnaverli.

Californ Carlo	Tak I		
Subject Code	PY	Subject Name	PHARMACY

Marks Obtained

28

Rank in Words

One * Two * Seven * Two

Rank in Figure

1272



VIJAYA INSTITUTE OF PHARMACEUTICAL SCIENCES FOR WOVE

ENIKEPADU, VIJAYAWADA-521 100

ENIKEPADU CON TIME TO THE TOTAL TO THE TOTAL

(VV)4

2021-2022



MSN Laboratories Private Limited

MSN House, Plot No.: C-24,

Sanath Nagar Industrial Estate, Sanath Nagar, Hyderabad, Telangana, Pincode: 500018. India.

CIN: U24239TG2003PTC041583

Phone: +91-40-30438600 Fax: +91-40-30438798

June 16, 2022

Ms.Sarakanam Pravalika

C/o Gangadhar Sarakanam Hno:-11-158 Sivalayam Street Krishna521108 Mobile No: 6303162728

Dear Ms.Sarakanam Pravalika.

Sub: Offer and Appointment Letter

This has reference to your application and the subsequent interview you had with us, we are pleased to offer you an employment with the following Terms & Conditions:

1. Designation:

You will be designated as "Assistant-Trainee", Grade "G01", in Quality Control Department based at MSN Laboratories Private Limited - MSNF-II-Kothur-Osd Location.

2. Remuneration:

Detailed compensation structure as Total Cost to Company Rs.150000/- is mentioned in the Annexure-I.

3. Documents to be Submitted:

Please bring all the following documents in original with Photostat copies of the same at the time of joining.

- a. Passport Size Color Photographs (Self) 7 nos. and Dependent-family members photograph 1 nos. each
- b. All Educational Certificates and any other Certificates related to specific Training and Skills
- c. Previous employment Service Certificate / Relieving Letter, if any
- d. Last Six Months Bank Statement
- e. Aadhaar Cards of self and dependent family members
- f. PAN Card
- g. Passport / Driving License
- h. A cancelled cheque leaf of active bank account
- i. Medical Certificate with Reports
- j. Non Judicial Stamp Paper worth Rs. 100/- in your name, for the purpose of Employment Agreement. You need to give us the Agreement of Employment on Non-Judicial Stamp paper, stating that, you will work with MSN Group of Companies for a minimum period of three years, from the date of joining.

Page 1 of 2

PRINCIPAL

WINDAYA INSTITUTE OF

PHARMACEUTICAL SCIENCES FOR WOMEN ENIKEPADU, VIJAYAWADA-521 108.

ammandations Their II. Co



Name: Sarakanam Pravalika

4. Medical Fitness:

This Offer and Appointment is subject to your medical fitness, for which you need to undergo Medical Examination at Company's Designated Medical Center as per Annexure-III.

5. Terms & Conditions:

- a. Your employment is governed by the detailed Terms & Conditions furnished in Annexure II.
- b. As discussed, you need to join us on or before June 20, 2022, failing which this offer and Appointment Letter stands withdrawn.
- c. This offer is subject to completion of your B Pharmacy and submission of all the certificates to the company. Further, please note that, in the event of noncompliance of submitting the pass certificate within the stipulated period i.e., on or before 31st December,2022, this offer will be Cancelled. In this regard, you are required to give declaration to the organization.

The Present Salary will be on the basis of Intermediate Your Salary will be revised to B Pharmacy Grade, from the date of Joining, after submission of Certificates.

Kindly arrange to send us your written confirmation within two working days, from the date of receipt of this offer letter as a token of your acceptance by signing on the Xerox copy of this letter, mentioning your Date of Joining.

Please feel free to contact Mr. Arjun Potturu, Contact No. 040-30438701, Email ID: arjun.potturu@msnlabs.com for further clarifications, if any.

We would like to take this opportunity to welcome you into our MSN family and wishing you a long & successful association with us.

Thanking you,

Yours sincerely,

For MSN Laboratories Private Limited

P Narsimha Rao

Senior Vice President - Group HR

ENIKEPADU ES VIJAYANADA SE

M ales

PRINCIPAL VIJAYA INSTITUTE OF

PHARMACEUTICAL SCIENCES FOR WOLLE'S ENIKEPADU, VIJAYAWADA-521 108. Page 2 of 2



June 16, 2022

Annexure-I

Ms.Sarakanam Pravalika Designation: Assistant-Trainee

Grade: G01

Department: Quality Control

TOTAL COST TO COMPANY

All figures in INR

All igu					
Salary Components	Per Month	Per Annum	Payment Frequency		
A. Monthly Salary			. C. C. Com Suprementation for control of the community of the control of the con		
Basic Pay	9500	114000	Monthly		
House Rent Allowance	124	1493	Monthly		
Education Allowance	0	0	Monthly		
Minimum Guaranteed Bonus	0	0	Monthly		
Statutory Bonus (Advance Payout)	700	8400	Monthly		
A - Monthly Gross Total	10324	123893			
B. Statutory Benefits					
PF (Employer Contribution)	1140	13680	Monthly		
ESI (Employer Contribution)	336	4027	Monthly		
Bonus / Ex-gratia	700	8400	Annual		
B - Statutory Benefits Total	2176	26107			
C. Fixed Total Cost to Company (A+B)	12500	150000			
D. Gratuity (As per the Gratuity Act, 1972)	457	5483			
Total Cost to Company (C+D)	12957	155483	The second secon		

Apart from the above, you are also eligible for following Benefits as per the Company Policy.

- Coverage under Group Personal Accident Policy
- Coverage under Group Term Life Insurance Policy
- You will be Covered Under ESIC Insurance Scheme

For MSN Laboratories Private Limited

P Narsimha Rao Senior Vice Presider

PRINCIPAL VIJAYA INSTITUTE OF PHARMACEUTICAL SCIENCES FOR WOLLEN

ENIKEPADU. VIJAYAWADA-521 105



Ref No: 23611049 13-Dec-2022

Kasireddy Naga Kalyani Durga



Dear Kasireddy,

We have greatly enjoyed our recent discussions with you and are pleased to offer you the role of Process Executive - Voice with Cognizant Technology Solutions India Private Limited ("Cognizant"). Your place of posting will be Hyderabad.

Your annual total compensation will be **INR 249,996**. Please see **Compensation and Benefits** for additional details on your compensation. Cognizant has considered **0 months** of your experience as relevant in this offer, which will be kept up-to-date in our records.

Your appointment will be governed by the terms and conditions of employment presented in **Employment Agreement**, as well as any rules, regulations and practices currently in place at the time of employment.

We request that you join us on or before 13-Dec-2022.

Please note:

- · This offer is subject to satisfactory professional reference checks
- This offer is valid for three (3) months from the date of offer. Any extension shall be at the discretion of Cognizant and shall be communicated to you in writing
- Prior to beginning work with Cognizant, you must provide evidence of your right to work in India and other documentation requested by Cognizant

We are delighted to welcome you to the team! You are joining Cognizant at an exciting time, and we know your fresh thinking and expertise will help us accomplish great things.

If you have any further questions or need clarification on this offer, please feel free to contact us.

Best regards,

For Cognizant Technology Solutions India Private Limited ("Cognizant"),

Shibu Balakrishnan

AVP -- HR

I have read the offer, understood and accept the above mentioned terms and conditions.

Signature:

Date:

PRINCIPAL
VIJAYA INSTITUTE OF
PHARMACEUTICAL SCIENCES FOR WOMEN
ENIKEPADU, VIJAYAWADA-521 108:

Car Dear

Regd Office: 115/535, Old Mahabalipuram Road, Okkiam Thoraipakkam, Chennai - 600 097



Compensation and Benefits

Name: Kasireddy Naga Kalyani Durga Designation: Process Executive - Voice

SI. No.	Description	Monthly	Yearly
1	Basic	7300	87,600
2	HRA*	2920	35,040
3	Conveyance Allowance*	800	9,600
4	Medical Allowance*	1250	15,000
5	Company's contribution of PF #	1800	21,600
6	Advance Statutory Bonus***	2000	24,000
7	Special Allowance*	4227	50,724
8	Company's Contribution of ESI @ 3.25% of Monthly Gross minus statutory exclusions	536	6,432
	Annual Gross Compensation		249,996
	Annual Total Compensation		249,996
	Company's contribution towards benefits (Medical, Accident and Life Insurance)	•	19,500
	Annual Total Remuneration		269,496

As an associate you are entitled to the following additional benefits:

- · Floating medical insurance coverage
- Round-the-clock group personal accident insurance coverage
- · Group term life insurance coverage
- Employees' compensation insurance benefit as per the Employee's Compensation Act
- Gratuity on separation after four (4) years and 240 calendar days of continuous service, payable as per the Payment of Gratuity Act

Leave and vacation:

• From your date of joining, you will be entitled to the following leave amounts as per your eligibility in line with statutory requirements. Leaves require manager approval in advance.

Category of Leave

- Earned Leave 18 days
- Sick Leave 12 days
- · Casual Leave 6 days

• From date of joining, women associates will be entitled to maternity leave based on eligibility as specified in the Maternity Benefit (Amendment) Application

• In addition to the above, as per Cognizant policy you are eligible for child adoption leave and paternity leave by adhering to the conditions as specified in the initia Leave Policy.

Regd Office: 115/535, Old Mahabalipuram

VIJAYA INSTITUTE OF PHARMACEUTICAL SCIENCES FOR WOMEN ENIKEPADU. VIJAYAWADA-521 108



Provident Fund Wages:

For the purpose of computing contributions to the Provident Fund, Pension Fund and EDLI Scheme, "Monthly Gross Salary" as stated in "Compensation and Benefits" of this letter, excluding "Advance Statutory Bonus" and "House Rent Allowance," will be considered. This does not include payments made through "Special Payout.

Determination of PF wages for the purpose of contribution: PF contribution shall be payable on the earned PF wages or PF wages as per this letter, whichever is lesser.

Employee State Insurance (ESI):

Eligible Wages Eligibility for ESI shall be decided by deducting the Advanced Statutory Bonus, Employer PF and ESI contribution from the monthly Gross Compensation (AGC/12) as stated in Compensation and Benefits of this letter.

Earned ESI Wages: Monthly ESI contribution will be computed on total remuneration paid to an associate in a particular month, including any recurring (or) ad hoc special payouts during the month.

ESI contribution shall continue until the end of the contribution period (April - September and October - March), if the associate contributes for at least one month in the contribution period.

* Flexible Benefit Plan:

Your compensation has been structured to ensure that you can apportion components of your salary to suit your individual preferences. This plan will enable you to

- Choose from an array of allowance or benefits
- 2. Redefine your salary structure within prescribed guidelines
- 3. Optimize your earnings

#* Advance Statutory Bonus is in line with the provisions of the Payment of Bonus Act

Note:

- · Any statutory revision of Provident Fund/ESI contribution or any other similar statutory benefits will result in a change in the net take-home salary. The Annual Gross Compensation will remain
- · Cognizant has made this offer in good faith after expending significant time and resources during the hiring process. We hope you will join us, but recognize your right to pursue another path. Your formal commitment to joining us forms the basis of further planning and client communication at Cognizant. If you decide not to join us after signing the offer letter, Cognizant reserves the right not to consider you for future career opportunities with the company. We look forward to welcoming you to Cognizant

Employment Agreement - Cognizant Technology Solutions India Private Limited

This Employment Agreement ("Agreement") is made effective as of 13-Dec-2022 between:

Cognizant Technology Solutions India Private Limited, a company incorporated under the Companies Act, 1956 with its registered office at 5/535, Okkiam Thoraipakkam, Old Mahabalipuram Road, Chennai - 600096; Temit Cladu, India; (hereinafter referred to as "Company" or "Cognizant," which shall, unless counter to the context or meaning thereof, be deemed to mean and include its successors and assigns of the ONE PART;

ENIKENADA Wada, Okkiam Syoraipakkam, Chenna

Regd Office: 115/535, Old Mahabalip (1997)

VIJAYA INSTITUTE OF PHARMACEUTICAL SCIENCES FOR WOLLE'S ENIKEPADU, VIJAYAWADA-521 102



AND

Kasireddy	Naga	Kalyani		(Age) (hereinafter referred		
"yourself," wh	ich shall, unle r heirs, execu	ess counter to t	he context o	r meaning thereof, be the OTHER PART.	deemed to	mean and

The Company and you are, wherever the context so requires, hereinafter collectively referred to as the "Parties" and individually as "Party."

RECITAL:

WHEREAS, you desire to be employed by the Company and the Company has made an employment offer ("Employment Offer Letter") to you and in pursuance thereof desires to employ you on the terms and conditions set forth below.

NOW, THEREFORE, in consideration of the mutual promises, covenants and conditions set forth herein, the Parties hereto mutually agree to the below mentioned terms and conditions governing your employment with Cognizant:

1. Duties and Responsibilities

- a) You agree that at all times during your employment with Cognizant, you will faithfully, industriously, and to the best of your skill, ability, experience and talent, perform any and all of the duties required of your position. In carrying out these duties and responsibilities, you shall comply with all policies, procedures, rules and regulations, both written and oral, as are announced or implemented by the Company from time to time, and shall honor and comply with all rules and statutory requirements under applicable law as amended from time to time, in letter and spirit.
- b) Your unprofessional behavior or misconduct in violation of Cognizant's Code of Business Ethics and/or other organizational policies shall entitle the Company to take appropriate disciplinary action(s) including termination of your employment.
- c) You shall, at all times, maintain satisfactory performance and upskill yourself in accordance with the business requirements of the Company. Unsatisfactory or poor performance shall entitle Company to take appropriate disciplinary action(s) including termination of your employment.

2. Place of Employment

You will be employed at any one of Cognizant's offices as per business requirements. The Company reserves the right to transfer you on a temporary or permanent basis to the other office locations, functions or departments within the Company and/or other affiliated entities and assign such other duties as may be deemed fit in the interest of the Company. The Company also reserves the right to require you to work remotely from time to time as per business needs or government mandate.

3. No Alternate Employment, No Conflict, Etc.

During your employment with the Company, you shall not, without the Company's prior written consent, directly or indirectly employ or engage with any other person, business or entity, whether or not for any gain or profit, irrespective of whether it is during or outside your hours of work in the Company. Additionally, you are not allowed to undertake any other gainful employment, engagement, business, assume any public office or private office, honorary or remunerative position, without prior written person, the Company. During your employment with the Company, you shall not directly the age in any conduct in conflict with or

Read Office: 115/535, Old Mahabatan Guide, Okulan Thoraipakkam, Chennai - 600 097

PRINCIPAL
VIJAYA INSTITUTE OF
PHARMACEUTICAL SCIENCES FOR WOLL &
ENIKEPADU, VIJAYAWADA-521 108



ANDHRA PRADESH STATE COUNCIL OF HIGHER EDUCATION APPGECET - 2022

Hall Ticket Number:	7190370024	Rank:	883
Candidate Name:	AVULA VARA LAKSHMI	Father's Name:	AVULA LINGAIAH
Gender:	FEMALE	Caste / Region:	BC_D/AU

PROVISIONAL ALLOTMENT ORDER (for PGECET CANDIDATES) PHASE-II

This is to inform that the options exercised by the candidate have been processed based on merit, rank, local area, gender, category, Special Reservation Category (CAP/PH/NCC/SPORTS) etc and the candidate has been allotted a seat in

VIJAYA INST OF PHARM SCI FOR WOMEN (VIPW1) VIJAYAWADA, KRI in REGULATORY AFFAIRS (PHRGAF) (RGS), under OC_GIRLS_AU category.

Tuition Fee fixed for the college/course is Rs.63000 /-.
Tuition Fee to be paid by the candidate is Rs. 63000 /-**

Instructions to Candidates:

- 1. Reporting through 'Candidates Login' from the website https://pgecet-sche1.aptonline.in/ through self-reporting system or from a nearby help line center.
- Take print out of two copies of joining report and report to the allotted college with all original certificates. Submit a copy of joining report and obtain acknowledgment on 2nd copy from the College where you have reported and retain the same withyou.
- Both self reporting and reporting at the allotted college is compulsory to retain the present allotted. The last date for self reporting and reporting at the
 allotted College is 14.11.2022 (before 5.00PM). Pay all necessary fees if any to the allotted college.
- If you do not report through Self-reporting system and/or not reporting at the alkotted college, the provisional allotment will be cancelled and you have no claim on the seat allotted.
- 5. If the academic credentials verified if found false at a later date, your allotment will be cancelled and you are also liable for criminal prosecution.
- 6. RGS or SFS [STIPENDARY], RGN OR SFN [NON-STIPENDARY].
- 7. Candidates, who got more than one allotment by virtue of their eligibility, can choose one college/course allotment through self-reporting system before joining the college. The other allotments will become null and void and they will be offered to other mentiorious candidates in next phase of counselling.
- 8. A candidate having more than one allotment, self reporting and reported at college but wish to change his college shall have to cancel his allotment from already reported college and can change to another college with in stipulated date.
- 9. Allotments in pharmacy colleges are subjected to approved of Pharmacy Council of India.
- All the Principals are requested to verify the original certificates viz caste, study, income and Degree certificates of the admitted candidates thoroughly and request to bring to the notice of the Convenor, APPGECET—2022 Admissions for any deviation.
- 11. Class work will commence from 14/11/2022



CONVENOR APPGECET - ADMISSIONS 2022

*** This computer generated Provisional Allotment Order does not require any authentication. *** 12/11/2022 02:49 PM

PRINCIPAL

VIJAYA INSTITUTE OF

PHARMACEUTICAL SCIENCES FOR WOMEN ENIKEPADU, VIJAYAWADA - 521 108



VIJAYA INSTITUTE OF PHARMACEUTICAL SCIENCES FOR WOMEN

Permitted by Govt. of A.P., Approved by AICTE, New Delhi Pharmacy Council of India, New Delhi, Affiliated to JNTUK & Certified by ISO 9001:2015



Date: 06.02.2023

STUDY CERTIFICATE

This is to certify that MS. MAPARTHI MADHURI, D/o. M. MANMADHA RAO is studying I M. PHARM of 2 years M. Pharm course (2022-2024) in Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada.

Our college is permitted by Andhra Pradesh State Government (G.O.Ms.No.84, dated 24-07-2009), affiliated to JNTU – Kakinada (Lr.No.B1/ Affi. Colleges List / 2009-10, dated 15-07-2009) and approved by AICTE – New Delhi, (File No.Ap-015/W.INDEGP / 2008-09, Dated 30-06-2009) and Pharmacy Council of India-New Delhi.

Principal
PRINCIPAL
VIJAYA INSTITUTE OF
PHARMACEUTICAL SCIENCES FOR WOMEN
ENIKEPADU, VIJAYAWADA-521 108.



VIJAYA INSTITUTE OF PHARMACEUTICAL SCIENCES FOR WOMEN

Permitted by Govt. of A.P., Approved by AICTE, New Delhi Pharmacy Council of India, New Delhi, Affiliated to JNTUK & Certified by ISO 9001:2015



Date: 06.02.2023

STUDY CERTIFICATE

This is to certify that MS. MAYARA VENKATA DURGA PRAVALLIKA, D/o. M. SRINIVASA RAO is studying I M. PHARM of 2 years M. Pharm course (2022-2024) in Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada.

Our college is permitted by Andhra Pradesh State Government (G.O.Ms.No.84, dated 24-07-2009), affiliated to JNTU – Kakinada (Lr.No.B1/ Affi. Colleges List / 2009-10, dated 15-07-2009) and approved by AICTE – New Delhi, (File No.Ap-015/W.INDEGP / 2008-09, Dated 30-06-2009) and Pharmacy Council of India-New Delhi.

PRINCIPAL
VIJAYA INSTITUTE OF
PHARMACEUTICAL SCIENCES FOR WOMEN
CHIKEPADU. VIJAYAWADA-FOA

ARTICLES PUBLISHED IN JOURNALS A.Y 2021-22

ISSN 2231-5705 (Print) 2231-5713 (Online) DOI: 10.52711/2231-5713.2022.00027

Vol. 12 |Issue-02| April - June | 2022 Available online at www.anvpublication.org www.asianpharmaonline.org

Asian Journal of Pharmacy and Technology Home page www.ajptonline.com



REVIEW ARTICLE

A Review on Transdermal Drug Delivery System

K. Naga Durga¹, P. Bhuvaneswari¹, B. Hemalatha^{1*}, K. Padmalatha²

Department of Pharmaceutics, Vijaya Institute of Pharmaceutical Sciences for Women, Vijayawada.

Department of Pharmacology, Vijaya Institute of Pharmaceutical Sciences for Women, Vijayawada.

*Corresponding Author E-mail:

ABSTRACT:

Nowadays about 74% of drugs are taken orally and are found not to be as effective as required. To improve such characters transdermal drug delivery system was emerged. Drug delivery through the skin to attain a systemic effect of a drug is commonly known as transdermal drug delivery and differs from traditional topical drug delivery. Transdermal drug delivery systems (TDDS) are dosage forms involves drug transport to viable epidermal and or dermal tissues of the skin for local therapeutic effect while a very major fraction of drug is transported into the systemic blood circulation. The adhesive of the transdermal drug delivery system is critical to the safety, efficacy and quality of the product. Topical administration of therapeutic agents offers many advantages over conventional oral and invasive methods of drug delivery. Several important advantages of transdermal drug delivery are limitation of hepatic first pass metabolism, enhancement of therapeutic efficiency and maintenance of steady plasma level of the drug. This review article provides an overview of advantages and disadvantages, factors affecting transdermal drug delivery, components and types of transdermal drug delivery, methods of preparation and methods of evaluation.

KEYWORDS: TDDS, Topical drug delivery, Systemic blood circulation, Skin.

1. INTRODUCTION:

Oral route is the popular route of drug delivery. Although it has some disadvantages including first pass metabolism, drug degradation in gastrointestinal tract due to enzymes, pH etc. To cross these problems, a novel drug delivery system was developed. In this transdermal delivery system medicated adhesive patches are prepared which deliver therapeutically effective amount of drug across the skin when it placed on skin. Medicated adhesive patches or transdermal patches are of different sizes, having more than one ingredient. Once they apply on unbroken skin they deliver active ingredients into systemic circulation passing via skin barriers.


A patch containing high dose of drug inside which is retained on the skin for prolonged period of time, which get enters into blood flow via diffusion process. Drug can penetrate through skin via three pathways-through hair follicals, through circulation passing via skin barriers. A patch containing high dose of drug inside which is retained on the skin for prolonged period of time, which get enters into blood flow via diffusion process. Drug can penetrate through skin via three pathways-through hair follicals, through sebaceous glands, through sweat duct. Transdermal drug delivery systems are used in various skin disorders, also in the management of angina pectoris, pains, smoking cessation and neurological disorders such as Parkinson's disease!

Received on 22.09.2021 Modified on 07.12.2021
Accepted on 08.01.2022 CAsian Pharma Press All Right Reserved
Asian J. Pharm. Tech. 2022; 12(2):159-166.
DOI: 10.57711/231.5713.2022.00022

— 159

First pass metabolisms of drug get avoided.
 Gastrointestinal incompatibilities get avoided.

1.1 Advantages of transdermal drug delivery system:





2231-5640 (Print) 2231-5659 (Online)

DOI: 10.52711/2231-5659.2022.00028

Vol. 12 | Issue-02| April - June | 2022

Available online at www.anvpublication.org

Asian Journal of Research in Pharmaceutical Sciences Home page www. ajpsonline.com



REVIEW ARTICLE

A Review on Emulgels as a Novel Approach for Topical Drug Delivery

N. Krishna Veni¹, P. Yashwanthi¹, B. Hemalatha^{1*}, K. Padmalatha²

Department of Pharmaceutics, Vijaya Institute of Pharmaceutical Sciences for Women, Vijayawada.

²Department of Pharmacology, Vijaya Institute of Pharmaceutical Sciences for Women, Vijayawada.

*Corresponding Author E-mail: balahemalatha25@gmail.com

ABSTRACT:

Topical drug delivery has been used for centuries for the treatment of local skin disorders. Drugs applied to the skin for their local action include antiseptics, antifungal agents, skin emollients, and protectants. Major disadvantage of gel is the delivery of hydrophobic drug. This can be overcome by emulgels. Emulgels have emerged as one of the most attractive topical delivery system as it has dual release control system i.e. gel and emulsion. Since hydrophobic drugs are not soluble in gel bases, it causes problem during the release of drug. When gel and emulsion are used in combination the dosage form is referred as emulgel. In emulgel formulation, the hydrophobic drugs could be incorporated into the oil phase and then oily globules are dispersed in aqueous phase resulting in o/w emulsion which can be mixed into the gel base. The major aim behind this formulation is delivery of hydrophobic drugs to systemic circulation via skin. A distinctive feature of topical drug delivery is the straight accessibility of the skin as a target organ for the treatment. This might be proving improved stability and release of drug than just incorporating drugs into gel base. The purpose of this review article is to exemplify emulgel for topical drug delivery, advantages and disadvantages of emulgel, physiology of skin, major components of emulgel, method of preparation, characterization and marketed products of emulgel.

KEYWORDS: Emulgel, Gel, Topical drug delivery, Skin disorders.

1. INTRODUCTION:


Drugs can be administered by numerous routes to human body namely oral, sublingual, rectal, parental etc. When drug administration through other routes fails or skin infections occur, transdermal delivery system could be employed. Large numbers of dermal products are existing for skin as liquids, powders etc. however the most accepted products are semisolid preparation. Among the semisolid preparations, the transparent gels are utilized both in cosmetics and in pharmaceutical preparations. Gels were prepared by entrapment of large amounts of aqueous or hydroalcoholic liquid in a network of colloidal solid particles. Gel formulations normally demonstrate improved drug release than ointments and creams.

Received on 22.09.2021 Modified on 15.12.2021 Accepted on 18.01.2022 OAsian Pharma Press All Right Reserved Asian J. Res. Pharm. Sci. 2022; 12(2):163-168. DOI: 10.52711/2231-5659.2022.00028



A main drawback is in the release of hydrophobic drugs. Such types of troubles were overcome by emulgel preparations. When gels and emulsion were mixed jointly emulgel is formed. Water phase containing gelling agent would convert an emulsion into an emulgel. Oil in water system was utilized for encapsulating lipophilic drugs whereas water in oil system was utilized for hydrophilic drug. Emulgels could be washed away without difficulty whenever needed and as well shows elegant properties. It in addition illustrates good penetration through the skin1. Emulgels with properties such as being thixotropic, greaseless, easily spreadable, easily removable, emollient, non-staining, water soluble, longer shelf life, biofriendly, transparent and pleasing appearance were used for dermatological purposes. Drug molecules can penetrate into the skin by three routes: through intact stratum corneum, through sweat ducts, or through sebaceous follicle. The surface of the stratum comeum presents more than 99% of the total skin surface accessible for percutaneous drug absorption. Passage through this outermost layer was the

163





L OF PHARMACEUTICAL RESEARCH

ISSN 2277-7105

REVIEW ON CURRENT MANAGEMENT OF GESTATIONAL TROPHOBLASTIC NEOPLASIA

Vydhani Uma Maheswari*1, Katragadda Uma Maheswari¹, Vallapu Prathyusha¹, Tabitha Sharon M.2, Kantamaneni Padmalatha3

¹Pharm. D V Year, Department of Pharmacy Practice, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada - 521 108.

²Assistant Professor, Department of Pharmacy Practice, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada - 521 108, Andhra Pradesh, India.

³Professor and Principal, Department of Pharmacology, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada - 521 108, Andhra Pradesh, India.

Article Received on 19 April 2022,

Revised on 09 May 2022, Accepted on 29 May 2022,

DOI: 10.20959/wjpr20227-24431

*Corresponding Author V. Uma Maheshwari Pharm. D V Year, Department of Pharmacy Practice, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada - 521 108.

ABSRACT

Gestational Trophoblastic Neoplasia (GTN) arises from placental tissue and is one of the few human malignancies that can be healed even if it has spread widely. GTN refers to a group of cancers that include hydatidiform moles, invasive moles, choriocarcinoma, and placental site trophoblastic turnours, all of which have various propensities for local invasion and spread. The purpose of this study was to summarise current knowledge of the natural history of molar pregnancy and persistent gestational trophoblastic neoplasia (GTN), as well as recent improvements in their treatment.

KEYWORDS: EMACO chemotherapy, Stages of GTN.

INTRODUCTION

GTN (gestational trophoblastic neoplasia) is a malignant lesion caused by aberrant placental trophoblast growth. GTN occurs in around 50% of instances due to molar pregnancy, 25% due to miscarriage or tubal pregnancy, and 25% due to term or preterm pregnancy. [1] [8] The majority of these tumours, invasive mole and CCA, always produce measurable quantities of human chorionic gonadotropin (hCG). They are highly sensitive to chemotherapy, with a cure rate of more than 90%. 90% of the time, a treatment can be achieved while maintaining ductive function. GTN diagnosis is one of the most important peeps in its treatment

Vol 11, Issue 7, 2022.

ISO 9001:2015 Certified Jodinal PHARIMAGEUTIGAL SCIENCES FOR VIDE

ENIKEPADU, YIJAYAWADA-521 108.

E-ISSN: 2348-1269, P-ISSN: 2349-5138



INTERNATIONAL JOURNAL OF RESEARCH AND ANALYTICAL REVIEWS (IJRAR) | IJRAR.ORG

An International Open Access, Peer-reviewed, Refereed Journal

A SYSTEMIC REVIEW ON ADVERSE EFFECTS ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY **DRUGS**

Indurthi Bharathi*¹, Sumaiya Salcem¹, Thati Sravani¹, Devagupthapu Kunthitha Devi¹, Purushothama Reddy K² and Kantamaneni Padmalatha³

1.Pharm. D V Year, Department of Pharmacy Practice, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada - 521 108.

2. Associate Professor, HOD of Department of Pharmacy Practice, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada - 521 108, Andhra Pradesh, India.

3. Professor and Principal, Department of Pharmacology, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada - 521 108, Andhra Pradesh, India. Andhra Pradesh, India.

ABSTRACT

The most popular medicine in the world is NSAIDS (nonsteroidal anti-inflammatory medications) due to their anti-inflammatory, analgesic, and antipyretic properties with a high number of people using them. More than 50 distinct compounds have been sold globally since F.Hoffmann discovered acetylsalicylic acid (aspirin) in the nineteenth century. NSAIDs are commonly given for chronic inflammatory diseases, but they are also widely used as OTC medications for a range of inflammatory processes, mild to moderate pain, and fever. Other clinical applications (such as low-dose aspirin for cardioprotection) are also common. COX 1 and COX 2 are two recognized isoenzymes of prostaglandin G/H synthase, often known as cyclooxygenase (COX), which serve as analgesics and anti-inflammatory agents. The pharmacodynamic activity of these medicines is predominantly mediated by COX2 inhibition, whereas COX1 inhibition is mostly responsible for the adverse effects. In the 1990s, NSAIDs that inhibit COX2 selectively were developed to lower the risk of gastrointestinal damage. The majority of studies found that using cyclooxygenase-2 (COX-2)-selective NSAIDs reduced the incidence of gastrointestinal, cardiovascular, and renal ADRs much more than using nonselective NSAIDs. Aspirin, ibuprofen, and naproxen are the well-known members of this class of medications, which are all accessible over-the-counter in most

URAR28B2989 | International Journal of Research and Analytical Reviews (IJRAR) www.ijrar.org

VIJAYA INSTITUTE OF PHASIJACEUTICAL SCIENCES FOR WOMEN ENIKEPADU, VIJAYAWADA-521 108.

IJRAR.ORG

E-ISSN: 2348-1269, P-ISSN: 2349-5138



INTERNATIONAL JOURNAL OF RESEARCH AND ANALYTICAL REVIEWS (IJRAR) | IJRAR.ORG

An International Open Access, Peer-reviewed, Refereed Journal

A REVIEW ON ANTIBIOTICS INDUCED ADVERSE DRUG REACTIONS

Devagupthapu Kunthitha Devi *1, Sumaiya Saleem¹, Indurthi Bharathi¹, Thati sravani¹
Purushothama reddy K.² and Kantamaneni Padmalatha³

- 1. Pharm D V year, Department of Pharmacy practice, Vijaya Institue of Pharmaceutical Sciences For Women, Enikepadu, Vijayawada- 521108, Andhra Pradesh, India
- Associate Professor, Department of Pharmacy Practice, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada- 521108, Andhra Pradesh, India
- 3. Professor and Principal, Department of Pharmacology, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada- 521108, Andhra Pradesh, India

ABSTRACT: The purpose of the study was to evaluate the cause, preventability and severity of adverse drug reactions that occurred in the several departments. The surgical patients receiving antibiotic therapy were included in the trial, and all necessary demographics, diagnosis, suspected ADRs, and suspected medication information were recorded. The Naranjo and WHO scales were used to assess ADR causation, while the Modified Hartwig and Siegel scale, Modified Schumock and Thornton scale, and Modified Schumock and Thornton scale were used to determine severity and preventability. Some antimicrobials have the potential to cause life-threatening adverse effects. Geriatric people are more likely to have adverse medication reactions due to physiologic changes that affect pharmacokinetic processes. More ADRs were reported from General Medicine and Pediatric departments, with the GIT (38.77 percent) and skin being the most afflicted organ systems (30.61 percent). Adverse medication reactions are a severe concern that increases morbidity, mortality, and health-care costs.

KEY WORDS: Antibiotics, Scales (Naranjo, Hartwig, Siegel), Adverse drug reactions, Hospitals.

INTRODUCTION: Antibiotics are commonly used in inpatient settings. Approximately half of all hospitalized patients receive at least one antibiotic during their stay (1), with an estimated 20% to 30% of inpatient days of antibiotic medication being avoidable (2). According to WHO, an adverse drug reaction (ADR) is any unpleasant and undesired response to a drug that occurs at dosages commonly used in man for prophylaxis, diagnosis, or therapy of disease, or the alteration of physiological function. ADRs frequently increase hospital stays, add to the financial burden, and raise the risk of death (3). Adverse effects are well-known risks of pharmacological therapy. Adverse drug reactions (ADRS) are a leading cause of death and morbidity in both inpatient and outpatient patients (4). Due to the inadequacies of drug studies in clinical ADR monitoring is required to make medications safer (5). In India, ADRs account for 0.7 percent of hospital admissions and 3.7 percent of hospitalized patients, with 1.8 percent of ADRs resulting in death (6).

22/82633 International Journal of Research and Analytical Reviews (IJRAR) www.ljrar.org

VIJAYA INSTITUTE OF



WORLD JOURNAL OF PHARMACEUTICAL RESEARCH

Volume 11, Issue 9, XXX-XXX.

Review Article

ISSN 2277-7105

REVIEW ON HEMATOPOITIC STEM CELL TRANSPLANTATION IN RHEUMATIC AUTOIMMUNE DISEASE

Thati Sravani*1, Sumaiya Saleem1, Indurthi Bharathi1, Devagupthapu Kunthitha Devi1,
Purushothama Reddy K.2 and Kantamaneni Padmalatha3

¹Pharm. D V Year, Department of Pharmacy Practice, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada – 521 108.

²Associate Professor, Department of Pharmacy Practice, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada – 521 108, Andhra Pradesh, India.

³Professor and Principal, Department of Pharmacology, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada – 521 108, Andhra Pradesh, India. Andhra Pradesh, India.

Article Received on 12 May 2022, Revised on 02 June 2022, Accepted on 23 June 2022 DOI: 10.20959/wjpr20229-24711

*Corresponding Author
Thati Sravani
Pharm. D V Year,
Department of Pharmacy
Practice, Vijaya Institute of
Pharmaceutical
Sciences for Women,
Enikepadu, Vijayawada—
521 108.
itatisravani@gmail.com

ABSTRACT

Stem cells develop in the embryo and produce a variety cells that develop to produce tissues during the organogenesis process. In addition, stem cell is characterized by an ability to indefinitely self-renew. Stem cells are broadly classified into embryonic stem cells and adult stem cells. Adult stem cells can be genetically reprogrammed to form pluripotent stem cells and exist in an Embryonic likestate. Human embryonic stem cells exist only briefly during the early stages of development. Adult stem cells are found all over the body and help to regenerate tissues after apoptosis or tissue repair. Adult stem cells called hematopoietic stem cells (HSC) produce blood and immune cells. Autoimmune responses are sustained due to the perennial persistence of tissue self-auto reactive lymphocytes. Immune reset is a process that results in the production of new self-tolerant cells after chemotherapy-induced lymphocyte destruction. Autologous HSC

transplantation is based on this (HSCT). Because of complaints related transplant-related mortality and morbidity, HSCT was initially limited to refractory autoimmune rheumatic disorders (AIRD). However, with a better understanding of patient selection, conditioning,

VIJAYA INSTITUTE OF PHARMACEUTICAL SCIENCES FOR WOMEN

ISO 9001:2015 Certified Journal

TOPIC ALL

Vol 11, Issue 9, 2022.

disupportive care, HSCT for AIRD has come a long way.



Volume 11, Issue 7, 1300-1305.

ISSN 2277-7105

REVIEW ON MIGRANE WITH AURA AND INCREASED RISK OF STROKE

Katragadda Uma Maheswari^{1*}, Vallapu Prathyusha¹, Vydhani Uma Maheswari¹, Navcen Yaradesi², Kantamneni Padmalatha³

¹Pharm. D V Year, Department of Pharmacy Practice, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada - 521 108.

²Associate Professor, Department of Pharmacy Practice, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada – 521 108, Andhra Pradesh, India.

³Professor and Principal, Department of Pharmacology, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada - 521 108, Andhra Pradesh, India.

Article Received on

19 April 2022,

1))

Revised on 09 May 2022, Accepted on 29 May 2022,

"DOI: 10.20959/wjpr20227-24429

*Corresponding Author K. Uma Maheshwari Pharm. D V Year, Department of Pharmacy Practice, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada - 521 108.

ABSTRACT

A number of studies have found that migraine is a risk factor for stroke on its own. Migraine with aura is linked to an increased risk of ischemic and hemorrhagic stroke. Migraines with and without aura, on the other hand, should be distinguished. Young women suffering from migraine with aura appeared to have a link between migraine and stroke. Based on the available literature, it was discovered in this review that ischemic stroke is closely associated with migraine with aura, young age, female sex, oral contraceptive use, and smoking habit in migraine with aura patients (MA).

KEYWORDS: Migraine, aura, risk, ischemic stroke, contraceptives, smoking.

INTRODUCTION

Migraines are characterized by throbbing pain or a pushing sensation. It is frequently accompanied by nausea, vomiting, and light and sound sensitivity. Migraines can last from hours to days. Migraines are divided into two types: migraine with aura (MA) and migraine without aura (MO). Migraine headaches are frequently preceded by warning signs. One-third of migraine sufferers, will experience one or more of the following warning symptoms

ACEUTICATION as auras, such as Having trouble speaking, feeling unbalanced or dizagravisual issues,

Vol 11, Issue 7, 2022.

ISO 9001:2015 Cehrifidd Aldu And N SITIT List PHARMACEUTICAL SCIENCES FOR VIO

ENIKEPADU, VIJAYAWADA-521 100.

winh.net



WORLD JOURNAL OF PHARMACEUTICAL RESEARCH

Volume 11, Issue 7, 1293-1299.

Review Article

ISSN 2277-7105

REVIEW ON MEDICATION NON-ADHERENCE METHODS TO IMPROVE MEDICATION ADHERENCE

Vallapu Prathyusha 1*, Katragadda Uma Maheswari 1, Yydani Uma Maheswari 1, Naveen Yaradesi², Kantamaneni Padmalatha³

¹Pharm. D V Year, Department of Pharmacy Practice, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada - 521 108.

²Assistant Professor, Department of Pharmacy Practice, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada - 521 108, Andhra Pradesh, India.

³Professor and Principal, Department of Pharmacology, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada - 521 108, Andhra Pradesh, India. Andhra Pradesh, India.

Article Received on 19 April 2022, Revised on 09 May 2022, Accepted on 29 May 2022, DOI: 10.20959/wjpr20227-24428

*Corresponding Author Vallapu Prathyusha Pharm. D V Year, Department of Pharmacy Practice, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada - 521 108.

ABSTRACT

Medication non adherence is a severe problem that impacts the patient health care and life. Patients who do not take their medications as prescribed have a significant worsening of their condition, increased health-care expenses and death.[1] A number of things are likely to have an impact on medication adherence called adherence barriers which could be handled in different ways. To increase drug adherence, it will be required to identify individual barriers for each patient and use appropriate ways to overcome them. Professionals in the medical field, such as Physicians, pharmacists, and nurses all play important roles in their patients' lives.

KEYWORDS: Medication adherence, Medication non adherence, Barriers.

INTRODUCTION

Medication non adherence is a major public health issue that has a significant impact on health outcomes and overall health-care expenses. The consequence of non adherence is waste of medication, disease progression, reduced functional abilities parjower quality of life, EUTICAL S

> VIJAYA INSTITUTE OF PHARMACEUTICAL SCIENCES FOR WOU'E'S

ISO 9001:2015 Certified Journal 1293

Vol 11, Issue 7, 2022.

1293



WORLD JOURNAL OF PHARMACEUTICAL RESEARCH

20/21/20/20/20 many many manda manda sa ang manda m

Volume 11, Issue 8, XXX-XXX.

Review Article

SJIF Impact Factor 8.084 ISSN 2277-- 7105

A REVIEW ON RATIONAL USE OF ANTIBIOTICS

Shaik Chandini^{1*}, Makkena Pallavi¹, Thommandru Aswini Teja¹, Shaik Sharmila, I. Reshma Naidu² and Kantamaneni Padmalatha³

¹Pharm D.V. Year, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada-521108, Andhra Pradesh, India.

²Assistant Professor, Department of Pharmacy Practice, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada-521108, Andhra Pradesh, India.

³Professor and Principal, Department of Pharmacology, Vijaya Institute of Pharmaceutical Sciences for Women, Enikepadu, Vijayawada-521108, Andhra Pradesh, India.



Article Received on 27 April 2022,

Revised on 18 May 2022. Accepted on 08 June 2022

DOI: 10.20959/wjpr20228-24507

*Corresponding Author Shaik Chandini

Pharm D.V. Year, Vijaya Institute of Pharmaceutical Sciences for Women,

nikepadu, Vijayawada-521108, Andhra Pradesh. India.

chandinisardhar@gmail.com

ABSTRACT

Antimicrobial resistance and its cost of use increases as a result of excessive and improper antibiotic usage which has become a global health issue. As a result, several strategies aiming at improving antibiotic therapy have developed up to this point. The goal of this study is to assess rational antibiotic usage and the influence of new limitation policies, as well as their reinforcement by infectious disease specialists, on hospital-wide antibiotic use. Individual difficulties stemming from unreasonable drug usage can have a long-term harmful impact on public well-being. Antibiotics are the most commonly used inappropriately, and thus disrupts the long-term sustainability of health gains in terms of both cost and productivity. There are currently worldwide and regional guidelines for establishing a government structure dedicated to monitoring and improving medicine use, as well

as conducting a national situation analysis in order to design a strategy. In response to country requests, the WHO Regional Office for Southeast Asia is currently conducting national situational studies to assist countries in developing coordinated action plans. After the study, it was concluded that antibiotic use was reduced and sensible antibiotic prescriptions were increased in hospitals as a result of the restricted policy.

KEYWORDS: Antibiotics, Rational use, Irrational More, Infectious Disease, Cost

Vol 11, Issue 8, 2022.

CONFERENCES, WORKSHOPS, WEBINARS PARTICIPATED BY THE STUDENTS

2021-22



Antiviral Research Society

(Reg. No: 144/2016 (TN Society Registration Act)

E-mail: antiviralresearch2016@gmail.com | Mobile: +91 93842 18275 | Website: antiviral.in

CERTIFICATE OF PARTICIPATION

National e-poster competition

This is to certify that Mr. / Ms. / Dr. S. Pravallika

has actively participated in in National e-poster competition organized by

ANTIVIRAL RESEARCH SOCIETY on 10th May 2022.



Organized by

Antiviral Research Society

IJAYA INSTITUTE OF

ENIKEPADU VIJAYAWADA-521 98

Dr. P. Selvam, M.Pharm., Ph.D., FNABS., FISNS (President - Antiviral Research Society)



Antiviral Research Society

(Reg. No: 144/2016 (TN Society Registration Act)

E-mail: antiviralresearch2016@gmail.com | Mobile: +91 93842 18275 | Website: antiviral.in

CERTIFICATE OF PARTICIPATION

National e-poster competition

This is to certify that Mr. / Ms. / Dr. 1. Machuri.

has actively participated in in National e-poster competition organized by

ANTIVIRAL RESEARCH SOCIETY on 10th May 2022.

Organized by

Antiviral Research Society

ENIKEPADU, VIJAYAWADA 521

THE WINDYN THE

Dr. P. Selvam, M.Pharm., Ph.D., FNABS., FISNS (President - Antiviral Research Society)



Antiviral Research Society

(Reg. No: 144/2016 (TN Society Registration Act)

E-mail: antiviralresearch2016(a gmail.com | Mobile: +91 93842 18275 | Website: antiviral.in

CERTIFICATE OF PARTICIPATION

National e-poster competition

has actively participated in in National e-poster competition organized by

ANTIVIRAL RESEARCH SOCIETY on 10th May 2022.

Organized by

Antiviral Research Society

PRINCIPAL

VIJAYA INSTITUTE OF

PHARMACEUTICAL SCIENCES FOR VALIETY

ENIKEPADU, VIJAYAWADA-51, 1964

Dr. P. Selvam, M.Pharm., Ph.D., FNABS., FISNS (President - Antiviral Research Society)